|[January 21, 2014]
Alitair Announces Issuance of an Additional Patent Covering its Platform Drug Delivery Technology, REA™
MORRISTOWN, N.J. --(Business Wire)--
Alitair Pharmaceuticals, Inc., a revenue-stage pharmaceutical company
with multiple respiratory product candidates in development, today
announced the issuance of U.S. Patent No. 8,617,602 from the United
States Patent and Trademark Office (USPTO) for its ion exchange resin
drug delivery technology, REA™.
"Our proprietary ion exchange resin drug delivery platform can be
utilized across a range of therapeutic classes and with many different
molecules," stated Alitair President and CEO, William W. Howard, Ph.D.
"The REA™ platform technology allows us to improve upon currently
available therapies and create new solid-oral formulations with less
frequent dosing schedules, boh of which have been shown to improve
"Being awarded this third patent is an important milestone in our
product development strategy and the growth of Alitair," continued
Howard. "We will likely use this technology to provide protection for
our orphan drug candidates, both of which can be formulated with our
REA™ technology. This would extend the life span of our orphan
candidates from 7 years to 20, further enhancing their value. We are
also actively seeking funding and development partners to build on the
momentum we've created and advance our product development programs."
About Alitair Pharmaceuticals:
Alitair Pharmaceuticals, Inc. develops medicines for the treatment of
respiratory illnesses. Alitair has out-licensed two prescription cough
candidates that use its proprietary ion-exchange resin technology
(REA™). The company has two orphan drug candidates under development.
Additional information about Alitair is available on the Alitair website
[ Back To Cloud Contact Center's Homepage ]